SF2a-TT15合成糖偶联疫苗在肯尼亚婴儿中的安全性与免疫原性:2a期年龄递减剂量递增双盲随机安慰剂对照研究
该2a期随机对照研究在肯尼亚开展,评估SF2a-TT15合成糖偶联疫苗在成人、儿童和婴儿中的安全性与免疫原性。婴儿队列随机接受不同剂量(2μg或10μg)及铝佐剂与否的疫苗或安慰剂,共216名婴儿入组。结果显示疫苗耐受良好,无疫苗相关严重不良事件,各疫苗组均诱导显著高于安慰剂的血清IgG GMT,最高GMT出现在铝佐剂10μg组。
要点
- SF2a-TT15在肯尼亚婴儿中耐受良好,无疫苗相关严重不良事件。
- 各剂量疫苗组均诱导显著高于安慰剂的抗SF2a LPS血清IgG GMT。
核心结论
- SF2a-TT15在肯尼亚婴儿中耐受良好且免疫原性强,支持进一步开发多价合成糖类志贺菌疫苗。
研究设计与样本
- 2a期、年龄递减、剂量递增、双盲、随机、安慰剂对照研究,在肯尼亚Kericho的KEMRI/WRAIR临床研究中心开展。
- 成人16例随机接受铝佐剂10μg疫苗或安慰剂(3:1);儿童16例同法随机;婴儿216例按3:3:3:3:1:1随机接受2μg或10μg疫苗(含或不含铝佐剂)或对应安慰剂。
- 疫苗于第0、90、270天肌内注射,末次注射后随访6个月;主要结局为所有队列不良事件发生率和婴儿队列免疫原性。
主要发现
- 婴儿队列共记录1235次不良事件,绝大多数(1226次,99%)与疫苗无关,严重程度以轻度(744次,60%)和中度(435次,35%)为主。
临床怎么用
- 该疫苗在目标婴儿人群中显示良好耐受性和强免疫原性,支持推进多价合成糖疫苗的进一步临床开发。
局限性
- 原文未报告对婴儿的保护效力数据,免疫原性结果不能直接等同于临床保护。
- 研究仅在肯尼亚单一中心开展,外推至其他流行区需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Shigella is the leading cause of morbidity and mortality in children younger than 5 years in low- and middle-income countries and is a major actor in antimicrobial resistance. An effective vaccine is urgently needed. SF2a-TT15, a conjugate featuring a synthetic 15-mer oligosaccharide surrogate of the O-antigen component of Shigella flexneri 2a (SF2a) lipopolysaccharide, was previously shown to be safe and immunogenic in a first-in-human study. We aimed to assess its safety and immunogenicity in infants from an endemic setting, the target population for a Shigella vaccine. METHODS: We conducted a phase 2a, age-descending, dose-escalating, double-blind, randomised, placebo-controlled study at the Clinical Research Center, Kenya Medical Research Institute/Walter Reed Army Institute of Research (Kericho, Kenya). Healthy adults aged 18-50 years and healthy children aged 2-5 years with a weight-for-age Z score of -2 or more were randomly assigned (3:1) to receive a 10 μg oligosaccharide dose of SF2a-TT15 adjuvanted with aluminium hydroxide (alum) or matching placebo. Healthy infants aged 9 months plus or minus 1 month with a weight-for-age Z score of -2 or more were randomly assigned (3:3:3:3:1:1) in a stepwise manner to receive a 2 μg oligosaccharide dose of non-alum-adjuvanted SF2a-TT15, a 2 μg oligosaccharide dose of alum-adjuvanted SF2a-TT15, a 10 μg oligosaccharide dose of non-alum-adjuvanted SF2a-TT15, a 10 μg oligosaccharide dose of alum-adjuvanted SF2a-TT15, non-alum-adjuvanted placebo, or alum-adjuvanted placebo, concomitantly with routine measles-rubella vaccination. Study products were administered intramuscularly on day 0, 90, and 270, with a 6-month follow-up after the last injection. The randomisation sequence was computer-generated and randomisation was stratified by cohort and treatment group. Syringes were over-labelled before injection to maintain masking; all clinical site teams were masked except the pharmacist team, including the pharmacy data quality monitoring team, and one person in the Institut Pasteur team. All participants were also masked. Progression between cohorts and dose levels was overseen by an independent data monitoring committee. The primary outcomes were the incidence of adverse events in all cohorts and immunogenicity in the infant cohort, as measured at days 14 and 28 after each injection and at the end of the study by serum IgG antibodies to SF2a lipopolysaccharide and proportion of responders. Safety endpoints were analysed in all participants receiving at least one injection and immunogenicity endpoints were analysed in the full analysis set and in the per-protocol analysis set. This study is registered with ClinicalTrials.gov, NCT04602975, and is completed. FINDINGS: Enrolment was between Oct 26, 2020, and Jan 5, 2022. 54 adults were screened for eligibility, 16 of whom were enrolled and randomly assigned to the adjuvanted 10 μg oligosaccharide dose (n=12) or adjuvanted placebo (n=4). 30 children were screened for eligibility, 16 of whom were enrolled and randomly assigned to the adjuvanted 10 μg oligosaccharide dose (n=12) or adjuvanted placebo (n=4). 413 infants were screened for eligibility, 216 of whom were enrolled and randomly assigned to the non-adjuvanted 2 μg oligosaccharide dose (n=46), the adjuvanted 2 μg oligosaccharide dose (n=44), the non-adjuvanted 10 μg oligosaccharide dose (n=41), the adjuvanted 10 μg oligosaccharide dose (n=43), non-adjuvanted placebo (n=22), or adjuvanted placebo (n=20). 112 (52%) of 215 infants in the safety analysis set were female and 103 (48%) were male. The SF2a-TT15 glycoconjugate was well tolerated and induced high serum IgG geometric mean titres (GMTs) to SF2a lipopolysaccharide in adults and children. In infants, SF2a-TT15 was well tolerated at both doses, adjuvanted or non-adjuvanted, with no vaccine-related serious adverse events. 202 (94%) of 216 infants had at least one unsolicited adverse event. 182 (90%) of these infants had adverse events considered not related to study products. No significant differences in the frequency of unsolicited adverse events were reported between any treatment groups (p>0·05 for all comparisons). 1235 adverse events were recorded in the infant cohort, most being unrelated to the study product (1226 [99%]) and of mild (744 [60%]) or moderate (435 [35%]) grading. At 28 days after each injection and for both doses, adjuvanted or non-adjuvanted, SF2a-TT15 induced significantly higher serum IgG GMTs to SF2a lipopolysaccharide compared with corresponding GMTs in placebo recipients (p=0·047 for the non-adjuvanted 2 μg oligosaccharide dose 28 days after the first injection and p<0·001 for all the other comparisons). The highest GMTs were elicited in the adjuvanted 10 μg oligosaccharide dose group (11 240·0 [95% CI 6187·6-20 418·0]), corresponding to a geometric mean ratio (GMR) of 55·0 (95% CI 30·3-99·7) with 93·8% (95% CI 79·2-99·2) of responders at 14 days after the first injection, and increased to 28 528·3 (18 805·1-43 279·0), corresponding to a GMR of 139·6 (79·5-245·2) with 100% (89·1-100·0) of responders at 14 days after the second injection, with no further increase after the boost vaccine. The adjuvanted 2 μg oligosaccharide dose group had significantly higher serum IgG GMTs to SF2a lipopolysaccharide than the non-adjuvanted 2 μg oligosaccharide dose group (p<0·001 at day 28 after the two first injections, p=0·022 at 28 days after the boost vaccine), but GMT were not significantly different between the adjuvanted and non-adjuvanted 10 μg oligosaccharide dose SF2a-TT15 groups (p>0·5 for all timepoints). At the end of the study, for both doses, adjuvanted or not, GMTs were decreased but were still significantly elevated compared with the placebo group (p<0·001). INTERPRETATION: SF2a-TT15 is well tolerated and strongly immunogenic in Kenyan infants, showing potential for further development. Available data support advancing a multivalent synthetic glycan-based Shigella vaccine. FUNDING: Gates Foundation, The Wellcome Trust, The European Union Seventh Framework Programme, Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases, and Institut Pasteur. TRANSLATION: For the Kiswahili translation of the abstract see Supplementary Materials section.
引用
- Sawe F, Koech L, Neffati S, et al. Safety and immunogenicity of the synthetic carbohydrate conjugate vaccine, SF2a-TT15, against Shigella flexneri 2a in infants in Kenya: a phase 2a, age-descending, dose-escalating, double-blind, randomised, placebo-controlled study. Lancet Infect Dis. 2026. PMID: 42617627. doi:10.1016/S1473-3099(26)00307-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。